Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.50 |
| ▸ | MLYCD | O95822 | 3/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4330123 | 0.85 | MLYCD (0.49) | MAPK14MLYCDHSP90AA1PSEN1PSEN2 | |
| SCHEMBL4335643 | 0.85 | MAPK14 (0.50) | MAPK14MLYCDHSP90AA1MAPK9MAPK10 | |
| SCHEMBL4342451 | 0.84 | MAPK14 (0.47) | MAPK14MLYCDHSP90AA1 | |
| SCHEMBL4521206 | 0.83 | MLYCD (0.56) | MAPK14MLYCDPSEN1PSEN2APH1B | |
| SCHEMBL4343873 | 0.83 | MLYCD (0.46) | MAPK14MLYCDHSP90AA1MAPK9MAPK10 | |
| SCHEMBL4332757 | 0.83 | MAPK14 (0.52) | MAPK14MLYCDHSP90AA1MAPK9MAPK10 | |
| SCHEMBL4337180 | 0.82 | MAPK14 (0.52) | MAPK14MLYCD | |
| SCHEMBL4338188 | 0.82 | MAPK14 (0.51) | MAPK14MLYCDHSP90AA1MAPK9MAPK10 | |
| SCHEMBL4337525 | 0.81 | MAPK14 (0.75) | MAPK14MLYCDMAPK9MAPK10MAPK11 | |
| SCHEMBL4333456 | 0.81 | MLYCD (0.47) | MAPK14MLYCDHSP90AA1PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2036905-B1 | PYRIDYLISOXAZOLE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2012-12-12 | — | — | EP | disclosed |
| US-8207203-B2 | Pyridylisoxazole derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20090306145-A1 | Pyridylisoxazole Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2036905-A1 | PYRIDYLISOXAZOLE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306145-A1 | Pyridylisoxazole Derivatives | CNKSR1, MAPK1, MAPK3 | MAPK14 43/4885MLYCD 4475/4885HSP90AA1 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.